“…Although global paediatric regulations define the paediatric population as being aged from birth to less than 16 or 18 years [ 30 ], the EMLc is intended for use in children up to the age of 12 years; therefore, the tool was designed to focus on this age group. Regulatory agency guidelines on paediatric pharmaceutical development have provided recommendations regarding the need for dose flexibility, patient acceptability, and excipient safety, as well the requirement to consider method of medicine administration and the use of appropriate measuring devices [ 18 ] and these aspects have been extensively discussed in the literature [ 1 , 5 , 19 , 21 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 ]. It is of key importance that paediatric patients can easily be administered the required dose and hence a formulation should allow the required flexibility of dosing according to age, body weight, or surface area, as appropriate.…”